Endpoint HealthTM is a precision-first therapeutics company based in Palo Alto, CA (USA), with the mission of developing and commercializing targeted therapeutic solutions in the precision immunology space, personalized to each patient’s biology and unique clinical needs. The company combines data science, therapeutics and therapy-guiding tests to understand each patient’s underlying biology and likely response to treatment, and develops and commercializes targeted therapeutic solutions intended to address those needs.
Biocartis and Endpoint Health announced their partnership agreement on November 3, 2020 which targets the development and commercialization of a novel companion diagnostic test on the Idylla™ Platform.
Critical Illness and Sepsis
Critical illnesses such as sepsis and Acute Respiratory Distress Syndrome (ARDS) are life-threatening conditions often characterized by a dysregulated host response to infection. Sepsis, a medical emergency characterized by organ dysfunction1 , is one of the main causes of morbidity and mortality in critically ill patients, affecting between 47 and 50 million people (about twice the population of Texas) every year.2 Globally, sepsis alone is associated with 11 million deaths per year3 and is one of the most expensive health conditions with annual healthcare costs estimated at over USD 60bn in the US alone.4 Sepsis is treatable and timely implementation of targeted interventions improves outcomes.5
Endpoint Health CDx
The Endpoint Health therapy-guiding test is designed to fit into the standard clinical workflow of current sepsis care. In current clinical practice, treatment decisions regarding treatment of sepsis or septic shock are often made based on professional judgement and clinical experience. Current patient workflows for septic shock include treatment monitoring and, absent vital signs improvement, discretional modification of therapeutic interventions. The Endpoint Health therapy-guiding test is administered upon suspicion or diagnosis of sepsis or septic shock. It is being designed to enable the assessment of a patient’s unique gene expression data, which are then processed by Endpoint Health’s proprietary algorithm. The analysis of these data would then be expected to provide information that is intended to assist the clinician in identifying the therapeutic strategy that is most likely to produce a positive result for the patient. In sum, this approach offers an opportunity to open the door to personalized medicine for critically ill patients suffering from sepsis or septic shock, a fragile patient population that could benefit from this innovative approach to selecting therapeutic interventions.
Development of the Endpoint Health Assay on Idylla™ is ongoing.
- 1Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–810.
- 2https://www.global-sepsis-alliance.org/
- 3https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)3298…
- 4https://journals.lww.com/ccmjournal/Fulltext/2020/03000/Sepsis_Among_Me…
- 5https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)3298…
What our Partner says about the collaboration
Endpoint Health’s mission is to bring life-saving targeted therapies to the right patient at the right time. Our partnership with Biocartis is a key element in our strategy to develop and deliver precision therapies to critically ill patients. We are excited about working together to address one of the biggest challenges in healthcare and to positively impact the outcomes and lives of patients.
Jason Springs, CEO and cofounder of Endpoint Health
